Narrative review summarizes diagnostic criteria and treatment evidence for hypogonadism in aging men with comorbidities
This narrative review examined the prevalence, diagnosis, and management of male hypogonadism in older men, particularly in the context of obesity and cardiometabolic disorders. The authors searched PubMed for relevant literature on hypogonadism, aging, obesity, diabetes, and related comorbidities, selecting original research articles, systematic reviews, meta-analyses, and clinical guidelines. The review addresses unresolved questions about diagnostic thresholds, the relationship between testosterone decline and aging, and the impact of treatment on symptoms and long-term health outcomes in older men.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 9, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Systematic review
- Sample size
- —
- Duration
- —
- Population
- Aging men, with particular focus on those with obesity, type 2 diabetes mellitus, and other cardiometabolic comorbidities (functional hypogonadism), and comparison to younger men with congenital or acquired disorders affecting the hypothalamic-pituitary-testicular axis (organic hypogonadism)
- Primary outcome
- Diagnostic criteria, etiological assessment, and impact of treatment on symptoms and long-term health outcomes in older men with hypogonadism
- Effect size
- —
- Significance
- Not reported
- Journal
- Maturitas
- Published
- Sep 9, 2026
Sources
Primary source
- Maturitas ↗Peer reviewed
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.